Abstract
Despite advances in medical and surgical therapy, cancer kills more than half a million people in the United States annually, and the majority of these patients succumb to metastatic disease. The traditional approach to treating systemic disease has been the use of cytotoxic chemotherapy. However, chemotherapy is rarely curative and toxicity is often dose limiting. In addition, the effects of chemotherapy are nonspecific, targeting both malignant and normal tissues. As a result, recent efforts increasingly have focused on developing agents that target specific molecules in tumor cells in order to both improve efficacy and limit toxicity. This review summarizes the history and current use of targeted molecular therapy for cancer, with a special emphasis on recently developed inhibitors of Focal Adhesion Kinase (FAK).
Keywords: Angiogenesis, carcinogenesis, focal adhesion kinase, targeted therapeutics, tyrosine kinase, Cancer, metastatic disease, cytotoxic chemotherapy, Tyrosine Kinase inhibitors, chronic myelogenous leukemia, RTK induces, CDK, Epidermal growth factor receptor, Vascular endothelial growth factor, flavopiridol
Anti-Cancer Agents in Medicinal Chemistry
Title: Evolving Therapies and FAK Inhibitors for the Treatment of Cancer
Volume: 10 Issue: 10
Author(s): Kelli Bullard Dunn, Melissa Heffler and Vita M. Golubovskaya
Affiliation:
Keywords: Angiogenesis, carcinogenesis, focal adhesion kinase, targeted therapeutics, tyrosine kinase, Cancer, metastatic disease, cytotoxic chemotherapy, Tyrosine Kinase inhibitors, chronic myelogenous leukemia, RTK induces, CDK, Epidermal growth factor receptor, Vascular endothelial growth factor, flavopiridol
Abstract: Despite advances in medical and surgical therapy, cancer kills more than half a million people in the United States annually, and the majority of these patients succumb to metastatic disease. The traditional approach to treating systemic disease has been the use of cytotoxic chemotherapy. However, chemotherapy is rarely curative and toxicity is often dose limiting. In addition, the effects of chemotherapy are nonspecific, targeting both malignant and normal tissues. As a result, recent efforts increasingly have focused on developing agents that target specific molecules in tumor cells in order to both improve efficacy and limit toxicity. This review summarizes the history and current use of targeted molecular therapy for cancer, with a special emphasis on recently developed inhibitors of Focal Adhesion Kinase (FAK).
Export Options
About this article
Cite this article as:
Bullard Dunn Kelli, Heffler Melissa and M. Golubovskaya Vita, Evolving Therapies and FAK Inhibitors for the Treatment of Cancer, Anti-Cancer Agents in Medicinal Chemistry 2010; 10 (10) . https://dx.doi.org/10.2174/187152010794728657
DOI https://dx.doi.org/10.2174/187152010794728657 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular Link Mechanisms between Inflammation and Cancer
Current Pharmaceutical Design The Re-Emergence of Aerosol Gene Delivery: A Viable Approach to Lung Cancer Therapy
Current Cancer Drug Targets Use of Single Nucleotide Polymorphism Array Technology to Improve the Identification of Chromosomal Lesions in Leukemia
Current Cancer Drug Targets Male Fertility-Implications of Anticancer Treatment and Strategies to Mitigate Gonadotoxicity
Anti-Cancer Agents in Medicinal Chemistry Comparison of the Growth Curves of Cancer Cells and Cancer Stem Cells
Current Stem Cell Research & Therapy Bortezomib and Arsenious Acid Synergistically Inhibit HL-60 Cells Viability in vitro and in vivo
Current Signal Transduction Therapy Genetic and Epigenetic Studies for Determining Molecular Targets of Natural Product Anticancer Agents
Current Cancer Drug Targets Impact of Magnetic Nanoparticles in Biomedical Applications
Recent Patents on Drug Delivery & Formulation Quadruplex DNA: A Promising Drug Target for the Medicinal Inorganic Chemist
Current Topics in Medicinal Chemistry Antitumor Carbazoles
Anti-Cancer Agents in Medicinal Chemistry Druggability of Mortalin for Cancer and Neuro-Degenerative Disorders
Current Pharmaceutical Design Polypharmacology in a Single Drug: Multitarget Drugs
Current Medicinal Chemistry The Discovery of CDP323, a Potent Alpha4 Integrin Antagonist
Current Immunology Reviews (Discontinued) Ureas: Applications in Drug Design
Current Medicinal Chemistry Protein Kinase C ζ Drives Sphingomyelin Metabolism in the Nucleus During Cell Proliferation
Current Chemical Biology Use of Corticosteroids in Critically Ill Septic Patients: A Review of Mechanisms of Adrenal Insufficiency in Sepsis and Treatment
Current Drug Targets TRICOM Vector Based Cancer Vaccines
Current Pharmaceutical Design Computational Models and Methods for Drug Target Prediction and Drug Repositioning
Combinatorial Chemistry & High Throughput Screening Screening for Infectious Diseases During Pregnancy: Which Test and Which Situation
Current Women`s Health Reviews Novel Therapeutic Strategies in Infection and Cancer Management
Current Aging Science